Consistent with these observations are the findings that gain of MYC (8q24) is associated with poor prognosis in prostate cancer, and that the pattern of 8p21-22 loss with 8q24 gain is an independent risk factor for systemic progression and cancer-specific death in this disease [33]. This evidence concerns the gene MYC and cancer.